Evolus, Inc. $EOLS Shares Acquired by Pinnacle Associates Ltd.

Pinnacle Associates Ltd. lifted its holdings in shares of Evolus, Inc. (NASDAQ:EOLS) by 15.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 782,365 shares of the company’s stock after acquiring an additional 107,490 shares during the period. Pinnacle Associates Ltd. owned 1.21% of Evolus worth $5,203,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in EOLS. State of Alaska Department of Revenue acquired a new position in Evolus during the third quarter worth approximately $26,000. Wexford Capital LP acquired a new position in Evolus during the third quarter worth approximately $37,000. Tower Research Capital LLC TRC increased its position in Evolus by 340.2% during the second quarter. Tower Research Capital LLC TRC now owns 7,364 shares of the company’s stock worth $68,000 after buying an additional 5,691 shares during the period. Aquatic Capital Management LLC acquired a new position in Evolus during the third quarter worth approximately $48,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Evolus during the third quarter worth approximately $62,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

Analyst Ratings Changes

EOLS has been the topic of several research analyst reports. HC Wainwright cut their price target on Evolus from $20.00 to $13.00 and set a “buy” rating on the stock in a research report on Tuesday, February 3rd. Mizuho set a $15.00 price target on Evolus in a research report on Wednesday, February 4th. Weiss Ratings raised Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday. BTIG Research reaffirmed a “buy” rating and set a $13.00 price target on shares of Evolus in a research report on Wednesday, March 4th. Finally, Wall Street Zen lowered Evolus from a “buy” rating to a “hold” rating in a research report on Sunday, March 15th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Evolus has an average rating of “Moderate Buy” and an average target price of $16.00.

Evolus Trading Down 1.2%

NASDAQ:EOLS opened at $6.50 on Friday. The firm has a market cap of $428.09 million, a P/E ratio of -9.70 and a beta of 1.28. The stock’s 50 day simple moving average is $5.04 and its 200-day simple moving average is $5.62. Evolus, Inc. has a 12-month low of $3.86 and a 12-month high of $10.62.

Evolus (NASDAQ:EOLS) last released its earnings results on Monday, May 4th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The firm had revenue of $73.14 million during the quarter, compared to analyst estimates of $72.52 million. During the same quarter in the prior year, the firm posted ($0.30) earnings per share. Research analysts forecast that Evolus, Inc. will post -0.41 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Rui Avelar sold 29,996 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $4.89, for a total value of $146,680.44. Following the transaction, the insider owned 430,542 shares of the company’s stock, valued at approximately $2,105,350.38. The trade was a 6.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider David Moatazedi sold 116,720 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $4.89, for a total value of $570,760.80. Following the completion of the transaction, the insider directly owned 618,369 shares in the company, valued at approximately $3,023,824.41. The trade was a 15.88% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 163,504 shares of company stock worth $797,184. Corporate insiders own 5.00% of the company’s stock.

Evolus Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.